America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What is the mechanism by which AOH1996 targets cancer cells specifically?
**Interview with Dr. Linda Malkas on Groundbreaking Cancer Treatment**
**Editor:** Welcome, Dr. Malkas. Thank you for joining us today to discuss your team’s exciting new drug, AOH1996, that targets solid tumors through what you describe as “targeted chemotherapy.” Can you elaborate on how this drug works?
**Dr. Malkas:** Thank you for having me. AOH1996 is designed to target a specific protein variant found in cancer cells known as PCNA. Think of PCNA as a bustling airline terminal—it has multiple gates for different types of flights. In cancer cells, this protein is uniquely mutated, which allows AOH1996 to selectively disrupt their DNA replication and reproductive cycle without affecting healthy cells. This targeted approach is what makes it potentially transformative for cancer treatment.
**Editor:** That’s fascinating! I understand that this drug has shown effectiveness across various cancers in clinical research. Could you share which types of cancers are specifically targeted?
**Dr. Malkas:** Certainly! Our research indicates that AOH1996 has been effective against several cancer types, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We’ve tested the drug on over 70 different cancer cell lines, and the results have been promising.
**Editor:** It sounds like this research has been quite extensive. What were some significant findings from your studies?
**Dr. Malkas:** One of the significant findings is that AOH1996 selectively kills cancer cells by disrupting their normal reproductive cycle. It acts like a blizzard, halting the flow of cancer cells while leaving healthy cells largely unaffected. These results are encouraging, and we are now looking to advance our findings through clinical trials in humans to further assess its effectiveness and safety.
**Editor:** It’s remarkable to see how long this research has taken. Could you tell us more about the journey of developing AOH1996 over the past two decades?
**Dr. Malkas:** Yes, it has indeed been a long journey. Our team at City of Hope focused on understanding the precise mechanisms of PCNA in cancer cells. Over the years, we invested significant efforts into determining how to develop a molecule that could specifically target the cancer variants of PCNA. Seeing this work come to fruition with AOH1996 has been incredibly rewarding.
**Editor:** Looking ahead, what are the next steps for AOH1996 in terms of clinical trials?
**Dr. Malkas:** The next steps involve rigorous clinical trials to evaluate its efficacy and safety in human patients. We will closely monitor the outcomes and hope to gather enough data to support larger studies. Our ultimate goal is to make AOH1996 a treatment option available to cancer patients who are in dire need of new therapies.
**Editor:** Thank you, Dr. Malkas, for sharing these insights with us. Your work is paving the way for hope in the fight against cancer, and we look forward to seeing the results of the upcoming trials.
**Dr. Malkas:** Thank you for the opportunity to discuss our research. I’m optimistic about the future of AOH1996 and its potential impact on cancer treatment.
